Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683710 | 0.94 | HTR2A (0.73) | HTR2AKMT2AMEN1ADORA2BRXFP1 | |
| SCHEMBL2794439 | 0.87 | HTR2A (0.74) | HTR2AKMT2AMEN1ADORA2BRXFP1 | |
| SCHEMBL684023 | 0.84 | HTR2A (0.58) | HTR2AKMT2AADORA2B | |
| SCHEMBL683711 | 0.83 | HTR2A (0.58) | HTR2AKMT2AADORA2BHTR1ACHRM1 | |
| SCHEMBL684364 | 0.82 | HTR1A (0.66) | HTR2AKMT2AMEN1ADORA2BRXFP1 | |
| SCHEMBL683671 | 0.81 | HTR2A (0.54) | HTR2AKMT2AADORA2BRXFP1POLB | |
| SCHEMBL682838 | 0.80 | HTR2A (0.57) | HTR2AKMT2AADORA2B | |
| SCHEMBL23974958 | 0.80 | ADORA2B (0.60) | HTR2AADORA2BRXFP1POLB | |
| SCHEMBL684065 | 0.79 | HTR2A (0.52) | HTR2AKMT2AADORA2BRXFP1 | |
| SCHEMBL684062 | 0.79 | HTR2A (0.52) | HTR2AKMT2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR2A 1201/4885KMT2A 1893/4885MEN1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.